Advertisement
BMY vs MRK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- BMY has delivered approximately 20% year-to-date gains amid strong demand for Eliquis and positive late-stage pipeline updates in oncology.
- MRK has outperformed with roughly 45% year-to-date returns, driven by Keytruda dominance and multiple pipeline advancements including acquisitions.
- Valuation metrics show BMY trading at a lower forward price-to-earnings ratio near 10x compared to MRK's elevated multiple exceeding 20x.
- Both companies operate primarily in oncology and face patent cliffs, yet MRK maintains larger scale with market capitalization exceeding $370 billion versus BMY's approximately $130 billion.
- Recent market activity reflects sector resilience, with BMY benefiting from raised guidance on key products and MRK advancing multiple Phase 3 readouts.
- Relative momentum favors MRK in the short term, while BMY offers potential value through cost discipline and diversified growth portfolio.
Introduction
Bristol-Myers Squibb (BMY) and Merck & Co. (MRK) represent two leading pharmaceutical companies with significant exposure to oncology and immunology. Investors and traders focused on the healthcare sector often compare these names to assess relative performance, valuation differences, and pipeline momentum within a defensive yet innovation-driven industry. This analysis examines observable factors such as recent stock behavior, business drivers, and market positioning to provide context for portfolio decisions in the current environment.
BMY Overview and Recent Performance
Bristol-Myers Squibb develops therapies in oncology, hematology, immunology, and cardiovascular areas, with key products including Opdivo, Eliquis, and Reblozyl. In recent weeks, the stock has reflected positive sentiment from strong Eliquis demand and raised full-year guidance, contributing to year-to-date gains near 20%. Pipeline catalysts, such as positive Phase 2 results for the GPRC5D-directed CAR T cell therapy arlocabtagene autoleucel in multiple myeloma, have supported sentiment. The shares have traded in a range influenced by broader market volatility and sector rotation, with a market capitalization around $130 billion.
MRK Overview and Recent Performance
Merck & Co. focuses heavily on oncology through its Keytruda franchise alongside vaccines, animal health, and emerging pipeline assets. Recent market activity has featured robust year-to-date advances exceeding 45%, supported by continued Keytruda growth, positive trial data, and strategic acquisitions such as Terns Pharmaceuticals. Guidance updates following second-quarter results reflected confidence in revenue expansion, with the company maintaining a larger market capitalization above $370 billion. Stock behavior has demonstrated relative strength amid sector tailwinds and multiple clinical milestones.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the highest-performing AI trading bots suited to prevailing market conditions from a library of hundreds of bots that trade thousands of tickers. These bots encompass varied trading styles, strategies, timeframes, and performance statistics, allowing selection based on specific risk parameters and historical metrics such as win rates or drawdowns. Only those demonstrating consistent results and alignment with current trends earn placement in the trending section. Review the platform for detailed bot profiles and live performance data to identify options matching individual objectives.
Head-to-Head Comparison
BMY and MRK both derive substantial revenue from oncology but differ in scale and diversification. MRK benefits from a dominant single-product franchise with broader global reach, while BMY maintains a more balanced portfolio including cardiovascular assets. Recent momentum has favored MRK on stronger price appreciation and pipeline breadth, whereas BMY trades at a discount on forward earnings multiples. Risk factors include patent expirations for both, with BMY showing greater sensitivity to generic competition offset by newer launches. Market sentiment reflects institutional interest in healthcare defensiveness, though relative positioning highlights trade-offs between growth consistency and valuation appeal.
Tickeron AI Verdict
Based on observable trend consistency, stability metrics, and recent catalysts, Tickeron’s AI models would currently assign a higher probabilistic preference to MRK over BMY. Stronger relative performance, pipeline visibility, and sector leadership contribute to this positioning, though outcomes remain subject to market variables and individual bot parameters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and MRK is a Buy.
BMY | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 41 Fair valued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | 30 | |
SMR RATING 1..100 | 22 | 79 | |
PRICE GROWTH RATING 1..100 | 44 | 38 | |
P/E GROWTH RATING 1..100 | 66 | 2 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (11) in the Pharmaceuticals Major industry is in the same range as BMY (41). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.
MRK's Profit vs Risk Rating (30) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (81). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79). This means that BMY’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as BMY (44). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (66). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | MRK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 52% | 2 days ago 50% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 41% | 2 days ago 48% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 49% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 42% |
| Advances ODDS (%) | 2 days ago 56% | 8 days ago 58% |
| Declines ODDS (%) | 7 days ago 53% | 6 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 60% | N/A |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 67% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while MRK’s FA Score has 3 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 3 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 6 bearish.
- MRK’s TA Score: 3 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +2.01% price change this week, while MRK (@Pharmaceuticals: Major) price change was -0.54% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.57%. For the same industry, the average monthly price growth was -4.15%, and the average quarterly price growth was +11.36%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
MRK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.57% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +1.62% | ||
| AMGN - BMY | 57% Loosely correlated | +0.85% | ||
| PFE - BMY | 57% Loosely correlated | +0.17% | ||
| NVS - BMY | 55% Loosely correlated | +0.98% | ||
| GSK - BMY | 53% Loosely correlated | +0.93% | ||
| ABBV - BMY | 51% Loosely correlated | +0.73% | ||
More | ||||
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.